480 related articles for article (PubMed ID: 22833239)
1. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.
Kumar U; Sankalp G; Sreenivas V; Kaur S; Misra D
Rheumatol Int; 2013 Apr; 33(4):1047-52. PubMed ID: 22833239
[TBL] [Abstract][Full Text] [Related]
2. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis.
Gore J; Silver R
Ann Rheum Dis; 2005 Sep; 64(9):1387. PubMed ID: 16100356
[No Abstract] [Full Text] [Related]
3. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
[TBL] [Abstract][Full Text] [Related]
4. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study.
Brueckner CS; Becker MO; Kroencke T; Huscher D; Scherer HU; Worm M; Burmester G; Riemekasten G
Ann Rheum Dis; 2010 Aug; 69(8):1475-8. PubMed ID: 19900936
[TBL] [Abstract][Full Text] [Related]
5. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis.
Herrick AL; van den Hoogen F; Gabrielli A; Tamimi N; Reid C; O'Connell D; Vázquez-Abad MD; Denton CP
Arthritis Rheum; 2011 Mar; 63(3):775-82. PubMed ID: 21360507
[TBL] [Abstract][Full Text] [Related]
6. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
Fries R; Shariat K; von Wilmowsky H; Böhm M
Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study.
Rubin LJ; Badesch DB; Fleming TR; Galiè N; Simonneau G; Ghofrani HA; Oakes M; Layton G; Serdarevic-Pehar M; McLaughlin VV; Barst RJ;
Chest; 2011 Nov; 140(5):1274-1283. PubMed ID: 21546436
[TBL] [Abstract][Full Text] [Related]
8. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
9. [Long-term effects of sildenafil in a patient with scleroderma-associated pulmonary hypertension and Raynaud's syndrome].
Rosenkranz S; Caglayan E; Diet F; Karasch T; Weihrauch J; Wassermann K; Erdmann E
Dtsch Med Wochenschr; 2004 Aug; 129(33):1736-40. PubMed ID: 15295684
[TBL] [Abstract][Full Text] [Related]
10. Oral sildenafil in skin ulcers secondary to systemic sclerosis.
Della Rossa A; Doveri M; D'Ascanio A; Tavoni A; Consensi A; Neri R; Bazzichi L; Bombardieri S
Scand J Rheumatol; 2011; 40(4):323-5. PubMed ID: 21639825
[No Abstract] [Full Text] [Related]
11. Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil.
Colglazier CL; Sutej PG; O'Rourke KS
J Rheumatol; 2005 Dec; 32(12):2440-2. PubMed ID: 16331780
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Botulinum Toxin B Injection for Raynaud's Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis.
Motegi SI; Uehara A; Yamada K; Sekiguchi A; Fujiwara C; Toki S; Date Y; Nakamura T; Ishikawa O
Acta Derm Venereol; 2017 Jul; 97(7):843-850. PubMed ID: 28358168
[TBL] [Abstract][Full Text] [Related]
13. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
Serri J; Legré R; Veit V; Guardia C; Gay AM
Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL
Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893
[TBL] [Abstract][Full Text] [Related]
15. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
[TBL] [Abstract][Full Text] [Related]
16. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.
Bettoni L; Geri A; Airò P; Danieli E; Cavazzana I; Antonioli C; Chiesa L; Franceschini F; Grottolo A; Zambruni A; Radaeli E; Cattaneo R
Clin Rheumatol; 2002 Jun; 21(3):244-50. PubMed ID: 12111631
[TBL] [Abstract][Full Text] [Related]
17. Perioperative sildenafil therapy for pulmonary hypertension in infants undergoing congenital cardiac defect closure.
El Midany AA; Mostafa EA; Azab S; Hassan GA
Interact Cardiovasc Thorac Surg; 2013 Dec; 17(6):963-8. PubMed ID: 23985411
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the pathogenesis and management of Raynaud's phenomenon and digital ulcers.
Herrick AL
Curr Opin Rheumatol; 2016 Nov; 28(6):577-85. PubMed ID: 27541182
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease.
Zeng WJ; Lu XL; Xiong CM; Shan GL; Liu ZH; Ni XH; Gu Q; Zhao ZH; Li JJ; He JG;
Clin Cardiol; 2011 Aug; 34(8):513-8. PubMed ID: 21678455
[TBL] [Abstract][Full Text] [Related]
20. Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension.
Wirostko BM; Tressler C; Hwang LJ; Burgess G; Laties AM
BMJ; 2012 Feb; 344():e554. PubMed ID: 22354598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
